Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KZR - Kezar Life Sciences Inc


IEX Last Trade
0.6006
0.003   0.433%

Share volume: 98,821
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.60
0.00
0.44%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
5%
Profitability 0%
Dept financing 2%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-4.47%
1 Month
-8.31%
3 Months
-12.24%
6 Months
-42.25%
1 Year
-63.15%
2 Year
-93.90%
Key data
Stock price
$0.60
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.54 - $1.61
52 WEEK CHANGE
-$0.62
MARKET CAP 
43.821 M
YIELD 
N/A
SHARES OUTSTANDING 
72.962 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
1.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$333,379
AVERAGE 30 VOLUME 
$323,116
Company detail
CEO: John Fowler
Region: US
Website: http://kezarlifesciences.com/
Employees: 81
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.

Recent news